Results 11 to 20 of about 90,332 (308)
The Amyloidosis Forum: a public private partnership to advance drug development in AL amyloidosis [PDF]
Orphanet Journal of Rare Diseases, 2020 Background Immunoglobulin light chain (AL) amyloidosis is a rare, multi-systemic disorder characterized by two disease processes: an underlying plasma cell dyscrasia that provides the source of pathologic light chains, and the resulting organ dysfunction
The Inaugural Amyloidosis Forum Panelists +1 more
doaj +2 more sources
Case Report and Literature Review of Cardiac Amyloidosis: A Not-So-Rare Cause of Heart Failure [PDF]
, 2023 Restrictive cardiomyopathy secondary to cardiac amyloidosis is an underdiagnosed cause of heart failure and it is associated with significant morbidity and mortality.
Alexandre, André +3 more
core +1 more source
Postgraduate Medical Journal, 2001 Abstract Amyloidosis is not a single disease but a series of diseases in which there is extracellular deposition of a protein which, although it may be derived from different and unrelated sources, folds into a β pleated sheet. There have recently been significant advances in elucidating the pathogenesis and in the ...
M F, Khan, R H, Falk
openaire +2 more sources
Blood Cancer Journal, 2022 Effective systemic therapies suppress toxic light chain production leading to an increased proportion of patients with light chain (AL) amyloidosis who survive longer albeit with end-stage renal disease.
Andrea Havasi +21 more
doaj +1 more source
Annals of Clinical Biochemistry: International Journal of Laboratory Medicine, 2012 The term amyloid describes the deposition in the extracellular space of certain proteins in a highly characteristic, insoluble fibrillar form. Amyloidosis describes the various clinical syndromes that occur as a result of damage by amyloid deposits in tissues and organs throughout the body.
Jennifer H, Pinney, Philip N, Hawkins
openaire +2 more sources
Navigating the Complex Web of Prescribing Amyloidosis Therapeutics: A Primer
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2022 Advancement in the diagnosis and treatment of transthyretin amyloid cardiomyopathy has made great strides in recent years. Novel therapeutics for transthyretin amyloidosis such as tafamidis, patisiran, and inotersen have shown significant benefits in a ...
Hongya Chen +6 more
doaj +1 more source
A case report of pulmonary amyloidosis recognized by detection of AA amyloid exclusively in alveolar macrophages [PDF]
, 2020 Amyloidosis is a rare condition in which tissue deposits of inert fibrillar protein result in organ damage and dysfunction. There are several types of amyloid fibrils.
Bychkov, Andrey +9 more
core +1 more source
Renal AA-amyloidosis in intravenous drug users - a role for HIV-infection? [PDF]
, 2012 Background: Chronic renal disease is a serious complication of long-term intravenous drug use (IVDU). Recent reports have postulated a changing pattern of underlying nephropathy over the last decades.
Grützmacher, Peter +17 more
core +1 more source
Clinical Amyloid Typing by Proteomics: Performance Evaluation and Data Sharing between Two Centres
Molecules, 2021 Amyloidosis is a relatively rare human disease caused by the deposition of abnormal protein fibres in the extracellular space of various tissues, impairing their normal function. Proteomic analysis of patients’ biopsies, developed by Dogan and colleagues
Diana Canetti +12 more
doaj +1 more source
Experimental approaches to study cerebral amyloidosis in a transgenic mouse model of Alzheimer's disease [PDF]
, 2004 Misfolding, aggregation and the accumulation of proteins in the brain are common characteristics of diverse age-related neurodegenerative diseases. Each of these neurodegenerative diseases is associated with abnormalities in the folding of a different
Meyer-Lühmann, Melanie
core +1 more source